Climb Bio (NASDAQ:CLYM) Upgraded by Wall Street Zen to Hold Rating

by · The Cerbat Gem

Wall Street Zen upgraded shares of Climb Bio (NASDAQ:CLYM – Free Report) from a sell rating to a hold rating in a research report report published on Saturday morning.

Other analysts also recently issued reports about the stock. Oppenheimer boosted their target price on shares of Climb Bio from $10.00 to $18.00 and gave the stock an “outperform” rating in a report on Tuesday, April 21st. Piper Sandler initiated coverage on shares of Climb Bio in a research report on Friday, February 13th. They set an “overweight” rating on the stock. Wedbush boosted their price objective on shares of Climb Bio from $15.00 to $17.00 and gave the company an “outperform” rating in a research report on Friday. B. Riley Financial initiated coverage on shares of Climb Bio in a research report on Tuesday, March 24th. They set a “buy” rating and a $26.00 price objective on the stock. Finally, Chardan Capital initiated coverage on shares of Climb Bio in a research report on Tuesday. They set a “buy” rating and a $22.00 price objective on the stock. Three analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Climb Bio has a consensus rating of “Buy” and a consensus target price of $19.80.

Get Our Latest Stock Analysis on Climb Bio

Climb Bio Stock Down 4.5%

Climb Bio stock opened at $11.37 on Friday. The company’s 50-day moving average price is $7.90 and its 200-day moving average price is $5.08. Climb Bio has a twelve month low of $1.13 and a twelve month high of $12.48. The company has a market cap of $543.14 million, a PE ratio of -14.58 and a beta of 0.02.

Climb Bio (NASDAQ:CLYM – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.06. As a group, sell-side analysts expect that Climb Bio will post -1.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CLYM. AQR Capital Management LLC bought a new position in Climb Bio during the first quarter valued at $27,000. Goldman Sachs Group Inc. bought a new position in Climb Bio during the first quarter valued at $147,000. Marshall Wace LLP purchased a new stake in shares of Climb Bio during the second quarter valued at $46,000. Qube Research & Technologies Ltd bought a new position in shares of Climb Bio in the second quarter worth about $43,000. Finally, Jane Street Group LLC bought a new position in shares of Climb Bio in the second quarter worth about $184,000. Institutional investors own 69.76% of the company’s stock.

About Climb Bio

(Get Free Report)

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.

Featured Articles